Mind-altering substances are (still) falling short in clinical trials

MIT Technology Review··18 分で読めます
シェア:X (Twitter)

Mind-altering substances are (still) falling short in clinical trials

This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over…

関連記事

AI ニュースを毎日受け取る

海外主要 AI メディアの最新情報を日本語でお届け。無料・いつでも解除可能。

無料・いつでも解除可能。登録すると X(Twitter)でも AI ニュースを自動投稿でお届けします。